OliX Pharmaceuticals, Inc

A226950

KR7226950004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
15,200 ^KRW	+3.33%		-0.65%	+4.25%

Mar. 22	OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors	CI
Mar. 20	OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors	CI

OliX Pharmaceuticals, Inc announced that it has received KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd.

May 30, 2022

On May 31, 2022, OliX Pharmaceuticals, Inc closed the transaction.

Latest news about OliX Pharmaceuticals, Inc

OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors	Mar. 21	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors	Mar. 19	CI
OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug	Dec. 22	CI
OliX Pharmaceuticals, Inc announced that it has received KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.	Dec. 14	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.	Dec. 06	CI
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration	Nov. 29	CI
OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia	23-06-13	CI
OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment	23-05-11	CI
OliX Pharmaceuticals, Inc Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA At Korea-US Digital BioHealth Business Forum	23-05-10	CI
OliX Pharmaceuticals, Inc Announces Positive Results from A Phase 2A Trial of Olx10010 for Hypertrophic Scar Treatment	23-04-28	CI
Olix Pharmaceuticals, Inc. Doses First Patient in Clinical Trial for Rnai Therapeutic Olx10212 for Dry and Wet Age-Related Macular Degeneration	23-03-27	CI
OliX Pharmaceuticals, Inc. Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia	23-03-23	CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.	22-12-11	CI
Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss	22-11-22	CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.	22-11-10	CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.	22-11-10	CI
OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration	22-08-03	CI
OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial	22-07-01	CI
Olix Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of Olx101a in Patients with Hypertrophic Scars	22-06-03	CI
OliX Pharmaceuticals, Inc announced that it has received KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd.	22-05-30	CI
OliX Pharmaceuticals, Inc announced that it has received KRW 57 billion in funding from a group of investors	22-05-26	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 15.000139 billion in funding from Shinhan Capital Co., Ltd. and other investors	22-05-22	CI
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 42.000013 billion in funding from a group of investors	22-05-22	CI
Olix Pharmaceuticals,Inc Identifies Effective Inhibition of Target Gene Expression and Delivery of Candidate to Brain for CNS Therapeutics	22-05-04	CI

Chart OliX Pharmaceuticals, Inc

Duration

Period

More charts

OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Companyâs product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
OLIX PHARMACEUTICALS, INC	+4.25%	184M
VERTEX PHARMACEUTICALS INCORPORATED	+7.41%	111B
REGENERON PHARMACEUTICALS, INC.	+11.25%	106B
BIONTECH SE	-12.66%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-8.77%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.47%	12.54B
LEGEND BIOTECH CORPORATION	-24.05%	8.09B

Bio Therapeutic Drugs